bio

The report provides an initial framework for the Pittsburgh region in both the public and private sectors to invest in Pittsburghs bioscience future. The document also assess the strengths and weaknesses of the regions bioscience capabilities and identifies opportunities for success. The framework includes steps for the region such as building a critical mass of cutting edge bioscience firms, continuing to sustain and further grow the regions research stature, address technology infrastructure gaps, and build an intellectual climate for the biosciences among many others.

The report by the Technology Partnership Practice of the Battelle Memorial Institute identifies the strengths, weaknesses, areas of competency, emerging care areas and strategies for the bioscience industry in the Peoria, Illinois region and offers recommendations.

The report by the Colorado Biotechnology Council outlines the strengths and weaknesses of Colorado in regards to the biotechnology industry. The council laid out several initiatives with the goal of accelerating the development of biotechnology in Colorado.

The report from the Los Angeles Regional Technology Alliance finds that despite many indications that show strong potential for growth, Southern Californias bioscience industry still faces challenges. The report highlights the strengths of the regions industry and assesses the ways that the industry can overcome its weaknesses.

The report concluded that todays vibrant biotechnology industry in Worcester is largely attributable to state economic development policies in place during the administration of Gov. Michael Dukakis. The authors point out both the presence of the University of Massachusetts Medical School in Worcester and the 250 percent increase in research funding the school has received since 1989 from the National Institutes of Health is most responsible for the region’s biotech strength.

The National Institutes of Health (NIH) issued the plan that calls for little or no modification to the Institutes existing efforts to capture royalties on federally-funded research. In conducting the report, NIH found that only four of the 47 FDA-approved drugs with $500 million per year in sales were partly developed with NIH-funded technologies.

The Biotechnology Industry Organization initiative offers the results of the first comprehensive survey of state government efforts to attract and grow the biotechnology industry. The report, prepared by Battelle Memorial Institute and the State Science and Technology Institute contains information from 48 states and shows state governments becoming increasingly active in recruiting and supporting biotechnology companies.

The General Accounting Office report examines how academic research institutions are implementing Health and Human Services (HHS) regulations governing individual investigators financial interests and how conflicts of interest are being managed. The report says presently, HHS method of handling conflicts in biomedical research is limited in its ability to preserve research integrity and protect human subjects.

Carnegie Mellon Universitys Center for Economic Development action plan reports that the Pittsburgh biotechnology cluster largely depends on the amount of available venture capital and the development of new technologies and that total funding levels must be increased to continue biotech development.

The Seventh Annual Economic Report of Connecticut United for Research Excellence shows Connecticut-based bioscience research and development investment in 2001 totaled $3.6 billion, an 18 percent increase over 2000. The study highlights several economic indicators that demonstrate the growth of the bioscience industry in Connecticut.